Definium's LSD Pill Eases Anxiety in Phase 3 Trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Definium Therapeutics said its LSD-based therapy DT120 significantly helped patients with generalized anxiety disorder in the first of two planned Phase 3 trials
- The Phase 3 anxiety study randomly assigned 214 patients to receive a single dose of DT120 or a placebo
- DT120 is described as Definium's "proprietary, pharmaceutically optimized" LSD pill
- This is Definium's second Phase 3 win in two months, following a prior late-stage success in major depression
- Definium characterized the anxiety study as the first of two large trials, with a second pivotal study still to read out
Why it matters: Definium has now posted back-to-back Phase 3 wins in two months — major depression and generalized anxiety disorder — putting its LSD pill DT120 on track for potential regulatory submissions across two psychiatric indications. With 214 patients in the first of two pivotal anxiety trials, a confirmatory positive read-out would give the company two distinct approval pathways from a single molecule.
Ask SkimNews
